
zzso plasma homocysteine levels have been associated with higher risks of cardiovascular disease, but the effects on disease rates of supplementation with zzso acid to lower plasma homocysteine levels are zzso Individual participant data were obtained for a zzso of 8 large, randomized, zzso trials of zzso acid supplementation involving zzso individuals at increased risk of cardiovascular zzso The analyses involved zzso comparisons of first events during the scheduled treatment zzso There were zzso major vascular events zzso major coronary events, zzso strokes, and zzso zzso zzso zzso and zzso zzso zzso acid allocation yielded an average zzso reduction in homocysteine zzso During a median follow-up of 5 years, zzso acid allocation had no significant effects on vascular zzso with rate ratios zzso confidence zzso of zzso zzso for major vascular events, zzso zzso for major coronary events, and zzso zzso for zzso Likewise, there were no significant effects on vascular outcomes in any of the zzso studied or on overall vascular zzso There was no significant effect on the rate ratios zzso confidence zzso for overall cancer zzso zzso zzso cancer mortality zzso zzso or zzso mortality zzso zzso during the whole scheduled treatment period or during the later years of zzso zzso supplementation with zzso acid to lower homocysteine levels had no significant effects within 5 years on cardiovascular events or on overall cancer or mortality in the populations zzso 

